

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



China Health Group Limited
中國衛生集團有限公司

(Carrying on business in Hong Kong as CHG HS Limited)

(Incorporated in Bermuda with limited liability)

(Stock Code: 673)

GRANT OF SHARE OPTIONS

This announcement is made pursuant to Rule 17.06A of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “Listing Rules”).

The board of directors (the “**Board**”) of China Health Group Limited (the “**Company**”) announces that on 26 April 2019 (“**Date of Grant**”), the Company granted share options (“**Options**”) to various eligible participants (“**Grantees**”) under the share option scheme of the Company adopted on 28 August 2012 (“**Share Option Scheme**”) to subscribe for a total of 321,994,763 ordinary shares of HK\$0.10 each of the Company (the “**Shares**”), subject to the acceptance of the Grantees.

Details of such grant of share options are set out below:

Date of Grant	:	26 April 2019
Exercise price of Options granted	:	HK\$0.18 per Share (which is the highest of (i) the closing price of HK\$0.071 on the Date of Grant; (ii) the average closing price of HK\$0.0792 per Share as stated in the daily quotation sheets issued by the Stock Exchange for the five business days immediately preceding the Date of Grant; and (iii) the par value of HK\$0.10 per Share)
Number of Options granted	:	321,994,763

Number of shares to be issued upon exercise of all Options granted	:	321,994,763 new shares
Closing price of the Shares on the Date of Grant	:	HK\$0.071
Validity period of the Options	:	The option period of the Options shall be ten years from the date of acceptance and the Options shall be lapse at the expiry of the option period (as defined under the Share Option Scheme).
Holding period	:	(i) 128,797,905 Options are exercisable from 27 April 2020; (ii) 96,598,429 Options are exercisable from 27 April 2021; and (iii) 96,598,429 Options are exercisable from 27 April 2022.

**Name of directors (“Director”)/
chief executive of the Company and
directors of the subsidiaries of the
Company**

	Position	Number of Options granted
Mr. Zhang Fan	Director & Chairman	4,000,000
Mr. Chung Ho	Director & CEO	30,000,000
Mr. Wang Jingming	Director	3,000,000
Mr. Weng Yu	Director	3,000,000
Mr. Huang Lianhai	non-executive Director	3,000,000
Mr. Qiu Peiyuan	non-executive Director	4,000,000
Mr. Xing Yong	non-executive Director	4,000,000
Mr. Xiao Zuhe	independent non-executive Director	3,000,000
Mr. Jiang Xuejun	independent non-executive Director	4,000,000
Mr. Du Yanhua	independent non-executive Director	3,000,000
Mr. Lai Liangquan	independent non-executive Director	3,000,000
Mr. Liu Hongdi	director of the subsidiaries of the Company	2,000,000
Mr. Liao Jijiang	director of the subsidiaries of the Company	3,000,000
Ms. Tang Wenji	director of the subsidiaries of the Company	1,000,000

In accordance with rule 17.04(1) of the Listing Rules, the grant of Options to each of the above directors/chief executive of the Company/directors of subsidiaries of the Company have been approved by the independent non-executive directors of the Company respectively (excluding the independent non-executive director of the Company who is the Grantee). Save as disclosed above, none of other Grantees is a director, chief executive or substantial shareholder of the Company or any of their respective associates (as defined under the Listing Rules).

By Order of the Board
China Health Group Limited
Zhang Fan

Chairman of the Board and Executive Director

Hong Kong, 26 April 2019

As at the date of this announcement, the Board comprises four executive Directors, namely, Mr. Zhang Fan (chairman), Mr. Chung Ho, Mr. Wang Jingming, and Mr. Weng Yu; four non-executive Directors, namely, Mr. Xing Yong, Mr. Wang Yuexiang, Mr. Huang Lianhai and Mr. Qiu Peiyuan; and four independent non-executive Directors, namely, Mr. Xiao Zuhe, Mr. Jiang Xuejun, Mr. Du Yanhua and Mr. Lai Liangquan.